Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IC 265
- Development stage
- Preclinical
- Lead developer
- Iacta Pharmaceuticals
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
IC 265 is a potent and selective small-molecule inhibitor of Spleen Tyrosine Kinase (Syk) currently under development by Iacta Pharmaceuticals for various ophthalmic conditions. Syk is a non-receptor cytoplasmic tyrosine kinase that plays a pivotal role in the signaling pathways of immune receptors, including B-cell receptors and Fc receptors, making it a critical mediator of inflammatory responses. By inhibiting Syk, IC 265 acts as a broad-spectrum anti-inflammatory agent, reducing the recruitment and activation of inflammatory cells in the eye. The drug is primarily being evaluated for the treatment of dry eye disease (keratoconjunctivitis sicca), where it has demonstrated the ability to reduce inflammation and ocular redness in Phase 2 clinical trials. It is also being investigated for allergic conjunctivitis and uveitis. Iacta has licensed the exclusive rights for ophthalmic indications of IC 265 in China and Southeast Asia to Zhaoke Ophthalmology.
- Other names
- PRT-2761PRT2761PRT 2761IC265 Ophthalmic Solution 1%
02
Targets
SYK (Spleen Tyrosine Kinase)
Beyond the preview
Go deeper on IC 265.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IC 265.